#China #Hong Kong #Innovative Medicines #Sino Biopharmaceutical #SBP Group

Sino Biopharmaceutical Limited Launches SBP Group

Sino Biopharmaceutical Limited, a prominent innovation-driven pharmaceutical company based in China, recently unveiled its new global brand, SBP Group, during its interim results meeting. This strategic move marks an important step in the company’s mission to advance its international presence and deliver innovative solutions to patients around the world.

A Symbol of Transformation

The name SBP signifies three core principles: Science, Breakthroughs, and Patients. This philosophy embodies the essence of the company’s operational strategy where scientific research serves as the foundation, breakthroughs are the goals, and the well-being of patients is the priority. Aligning with the company motto, “Science for a Healthier World,” SBP Group is set to solidify its commitment to global health improvement.

The launch of SBP Group symbolizes Sino Biopharmaceutical's transition from being a domestic leader in China to becoming a significant global player. This transformation is being driven by two essential vectors: product globalization, aimed at creating a diverse portfolio of innovative assets through internal research and development (R&D) as well as strategic acquisitions; and business globalization, which focuses on forging international partnerships and expanding direct commercial efforts in key markets worldwide.

Committed to Global Partnerships

According to Ms. Theresa Tse, Chairwoman of the Board, “2026 marks the first year of executing our globalization strategy, and we have made strong progress.” The SBP Group is not just focused on sending products abroad; it's equally dedicated to bringing cutting-edge therapies from international markets to China. The goal, facilitated by an AI-driven, fully integrated R&D platform, is to foster breakthroughs in science that ultimately benefit a broader patient demographic and enhance public health globally.

Driving Financial Success

To date, Sino Biopharmaceutical has engaged in four out-licensing transactions with multinational corporations (MNCs), achieving upfront payments exceeding $1 billion, with a potential total deal value of over $7 billion. Among this year’s significant achievements are the exclusive licensing arrangements with major pharmaceutical companies such as Sanofi and AstraZeneca.

Specifically, Sanofi has obtained rights to rovadicitinib, a groundbreaking dual JAK/ROCK inhibitor, through a deal valued at up to $1.53 billion. Meanwhile, AstraZeneca has secured the exclusive rights to TQC3721, an inhaled PDE3/4 inhibitor aimed at treating chronic obstructive pulmonary disease (COPD), valued at up to $1.9 billion. These milestones not only bolster the company’s revenue but also underscore its capability in the pharmaceutical market.

A Broad Product Portfolio

Sino Biopharmaceutical, under the SBP Group brand, boasts a comprehensive scope across the pharmaceutical value chain, including R&D, manufacturing, and commercialization. Its diverse product line features both biologics and small molecule drugs, maintaining a commanding presence in four critical therapeutic areas: oncology, liver and cardiometabolic diseases, respiratory and autoimmune diseases, and surgical/analgesic applications.

The successful transition to the SBP Group brand reflects a multidimensional strategy that combines innovation, collaboration, and a deep commitment to improving patient outcomes on a global scale. As Sino Biopharmaceutical Limited steps confidently into the future, the health sector can undoubtedly expect significant advancements and positive changes stemming from this ambitious initiative.

In conclusion, the introduction of SBP Group marks a pivotal chapter in the ongoing narrative of Sino Biopharmaceutical’s evolution. As the company forges ahead, its dedication to harnessing science for the greater good will undoubtedly resonate throughout the international medical and patient communities.